Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2020 09/16/2020 09/17/2020 09/18/2020 09/21/2020 Date
75.51(c) 75.64(c) 78.36(c) 79.38(c) 76.88 Last
1 537 011 1 689 612 3 097 149 4 440 889 573 948 Volume
+0.23% +0.17% +3.60% +1.30% -3.15% Change
More quotes
Financials (USD)
Sales 2020 1 862 M - -
Net income 2020 775 M - -
Net cash position 2020 704 M - -
P/E ratio 2020 19,0x
Yield 2020 -
Sales 2021 2 026 M - -
Net income 2021 128 M - -
Net cash position 2021 839 M - -
P/E ratio 2021 111x
Yield 2021 -
Capitalization 14 396 M 14 396 M -
EV / Sales 2020 7,35x
EV / Sales 2021 6,69x
Nbr of Employees 3 001
Free-Float 99,4%
More Financials
Company
BioMarin Pharmaceutical Inc. specializes in the development, production, sales and marketing of biopharmaceutical products. Net sales break down by source of income as follows: - sale of medications (97.5%): designed to treat problems caused by overactive lysosomal enzyme activity, hyperphenylalaninemia and autoimmune diseases; - royalties and revenues from partnership agreements (2.5%). Net sales are distributed... 
More about the company
Notations Surperformance© of BioMarin Pharmaceutical Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BIOMARIN PHARMACEUTICAL INC.
09/15BIOMARIN PHARMACEUTICAL : to Participate in Four Upcoming Virtual Investor Confe..
PR
09/14BIOMARIN PHARMACEUTICAL : Announces Presentation of Vosoritide Phase 3 Data in C..
AQ
09/09BIOMARIN PHARMACEUTICAL INC : Regulation FD Disclosure (form 8-K)
AQ
09/08BIOMARIN PHARMACEUTICAL : Announces The Lancet Publishes Detailed Vosoritide Pha..
PR
09/08BIOMARIN PHARMACEUTICAL : to Participate in Two Upcoming Virtual Investor Confer..
PR
08/20BIOMARIN PHARMACEUTICAL : Submits New Drug Application to U.S. Food and Drug Adm..
PR
08/20BIOMARIN PHARMACEUTICAL : Receives Complete Response Letter from FDA for Valocto..
AQ
08/19Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pha..
PR
08/19Health Care Shares Fall Amid Deal News -- Health Care Roundup
DJ
08/19Target, Momenta Pharmaceuticals rise; BioMarin, TJX fall
AQ
08/19BIOMARIN PHARMACEUTICAL : FDA blocks much-anticipated BioMarin hemophilia gene t..
AQ
08/19U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive
RE
08/19BIOMARIN PHARMACEUTICAL : Receives Complete Response Letter (CRL) from FDA for V..
PR
08/13BIOMARIN PHARMACEUTICAL : European Medicines Agency Validates BioMarin's Marketi..
PR
08/10BIOMARIN PHARMACEUTICAL : to Participate in Two Upcoming Virtual Investor Confer..
PR
More news
News in other languages on BIOMARIN PHARMACEUTICAL INC.
08/19Aktien New York Schluss: Dow und Nasdaq fallen trotz Apple-Meilenstein
08/19Aktien New York: Dow und Nasdaq verhalten im Plus - Apple mit Meilenstein
08/19Aktien New York: Dow am Mittwoch gefragter als der Nasdaq 100
08/05Wall Street : le Nasdaq poursuit sa hausse vers l'infini
08/04Wall Street : le Nasdaq poursuit sa hausse vers l'infini
More news
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 111,25 $
Last Close Price 79,38 $
Spread / Highest target 137%
Spread / Average Target 40,1%
Spread / Lowest Target 0,78%
EPS Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Steve Maricich Medical Director-Clinical Sciences
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICAL INC.-6.11%14 396
CSL LIMITED2.49%94 051
BIOGEN INC.-7.50%43 454
SAMSUNG BIOLOGICS CO.,LTD.75.06%43 141
WUXI BIOLOGICS (CAYMAN) INC.93.72%33 491
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.149.70%29 310